Spots Global Cancer Trial Database for Clinical Study of CD70-targeted CAR-T Therapy for Advanced/Advanced Renal Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Clinical Study of CD70-targeted CAR-T Therapy for Advanced/Advanced Renal Cancer
Official Title: A Phase I Clinical Study of CD70-targeted CAR-T Therapy for Advanced/Advanced Renal Cancer
Study ID: NCT05420519
Interventions
Study Description
Brief Summary: This is a phase I clinical study to evaluate the safety and tolerability of CAR-T in patients with advanced/metastatic renal cell carcinoma, and to obtain the maximum tolerated dose of CAR-T and phase II Recommended dose.
Detailed Description: This is a single-center, single-arm, open-label study. Intravenous infusion group have 4 dose groups, adopting a dose-escalating 3+3 design, and plan to recruit about 12 subjects with CD70-positive advanced/metastatic renal cell carcinoma in Dose discovery phase and 12 subjects in dose expansion phase.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
The Second People's Hospital of Shandong Province, Jinan, Shandong, China
Contact Details
Name: Jianfeng Bi, M.D
Affiliation: The Second People's Hospital of Shandong Province
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
